-42%

est. 2Y upside i

HealthcareSeries B

Rank

#3155

Sector

Healthcare

Est. Liquidity

~5Y

Data Quality

Data: Low

Given the severe preference overhang ($38.5M vs estimated $70M valuation) and high incumbent threat, the risk of common stock being wiped out is substantial.

Last updated: July 3, 2026

Bull (30%)+44%

Sustained high growth and expansion into new geographies could allow Sukino to command a premium multiple of 6x forward revenue, driven by category leadership in post-acute care and potential IPO window.

Base (25%)-40%

Growth moderates but remains strong; multiple converges to public comp range of 2.5x, resulting in modest decline in total equity value.

Bear (45%)-100%

Intense competition from incumbents like Apollo and Fortis compresses multiples below 2x, and preference stack dominates; common stock recovers zero as exit value falls below total funding.

Est. time to liquidity~5.0 years

Preference Stack Risk

severe

Funding Intensity

55%

Total funding of $38.5M represents 55% of estimated entry valuation, giving preferred stockholders a strong liquidation preference over common.

Dilution Risk

low

Company is profitable and recently raised $31M, so no near-term dilution expected.

Secondary Liquidity

none

No secondary market activity reported.

View all 10 open roles at Sukino →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Sukino's data — designed to show you've done your homework.

  • 1

    “How does Sukino plan to defend against Apollo and Fortis entering post-acute care?”

  • 2

    “What is the unit economics of a typical 30-day patient stay?”

  • 3

    “Given the preference stack, how would you model my common equity dilution in a future financing round?”

Community

Valuation Sentiment

Our model estimates -42% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.